Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors

• Our medicines

  

  • Arimidex
  • Crestor
  • Nexium
  • Seroquel
  • Symbicort
  • View all medicines

• Our responsibility

  

  • Animal research
  • Clinical trials
  • Patient safety
  • Sales and marketing
  • Pharmaceuticals in the environment
  • more information

• CEO interview

  • Video1
    David Brennan, our CEO discusses 2009 results and the outlook for the next five years.
    View part twoDownload podcast, vodcast and transcript

• Latest news collapse

  • 11 March 2010 AstraZeneca Comments On FDA Joint Advisory Committee Meeting On Post-Marketing Safety Studies For The Use Of LABAs In Asthma

    On 10 and 11 March 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) – including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees – discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT (budesonide/formoterol fumarate dihydrate).

  • 11 March 2010 AstraZeneca Extends Branded Generics Capability With Torrent Agreement

    AstraZeneca today announced a license and supply agreement with Torrent Pharmaceuticals Ltd.  Torrent will supply to AstraZeneca a portfolio of generic medicines for which Torrent already has licenses in a range of countries.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next